✦ LIBER ✦

Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia

✍ Scribed by Borje S. Andersson; Cassian Yee; Michael J. Keating; Kenneth B. McCredie; Mario A. Luna; Kathleen K. Hui

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 620 KB
Volume: 65
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19900301)65:5<1079::aid-cncr2820650506>3.0.co;2-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Subacute pulmonary failure complicating

Subacute pulmonary failure complicating therapy with high-dose ara-C in acute leukemia

✍ Borje S. Andersson; Brad M. Cogan; Michael J. Keating; Elihu H. Estey; Kenneth B 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 1 views

High dose cytosine arabinoside (HDARAC)

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

✍ Seth A. Rudnick; Edwin C. Cadman; Robert L. Capizzi; Roland T. Skeel; Joseph R. 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

Thirteen leukemic patients with disease refractory to conventional chemotherapy were treated with 1.0 to 7.5 g/m2 of Cytosine Arabinoside (Ara-C) over 29 drug cycles. Drug infusions were spaced at 12-hour intervals; a maximum of four doses was administered over 36 hours. After single dose tolerance

Bulbar and pseudobulbar palsy complicati

Bulbar and pseudobulbar palsy complicating therapy with high-dose cytosine arabinoside in children with leukemia

✍ Shaw, Peter J. ;Procopis, Peter G. ;Menser, Margaret A. ;Bergin, Mary ;Antony, J 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 387 KB

Three of 38 children given high-dose cytosine arabinoside therapy developed a previously undescribed complication. Neurological problems are a frequent occurrence in patients given this therapy, particularly cerebellar ataxia, but the development of bulbar and pseudobulbar palsy has not been reporte

Acute polyneuropathy after high dose cyt

Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia

✍ Harry Openshaw; Neal E. Slatkin; Anthony S. Stein; David R. Hinton; Stephen J. F 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 699 KB

## BACKGROUND. Peripheral nerve toxicity has been reported but is not a commonly recognized complication of high dose cytosine arabinoside (HDAC) therapy. This study was undertaken to estimate the prevalence and describe the clinical spectrum of acute polyneuropathy associated with HDAC therapy fo

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia

✍ Ronald S. Walters; Hagop M. Kantarjian; Michael J. Keating; William K. Plunkett; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days. Overall 16 patients (36%

Low-dose cytosine arabinoside (Ara-C) th

Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia

✍ Jane N. Winter; Daina Variakojis; Ellen R. Gaynor; Richard A. Larson; Kenneth B. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 664 KB